Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Key prostate cancer news from GU 2019

Simon Crabb • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer Abiraterone Darolutamide Enzalutamide
ARAMIS ARCHES LATITUDE

Simon Crabb, MBBS, MRCP, PhD, of the University of Southampton, Southampton, UK, summarizes key prostate cancer news presented at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. Dr Crabb reviews promising results from the LATITUDE study (NCT01715285), the ARCHES trial (NCT02677896) and the ARAMIS trial (NCT02200614).

More from Simon Crabb

1:25
ProCAID: capivasertib plus docetaxel and prednisolone chemotherapy for the treatment of mCRPC
Simon Crabb • 19 Feb 2022
0:50
Maintenance therapy for patients with advanced urothelial carcinoma
Simon Crabb • 19 Feb 2022
1:36
ATLANTIS rucaparib arm: maintenance PARPi following chemotherapy for mUC
Simon Crabb • 19 Feb 2022
1:35
PARP inhibitors for the treatment of metastic castration-resistant prostate cancer
Simon Crabb • 19 Feb 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals